DIAGNOS Inc. announced the commencement of its innovative deployment in an advanced screening program at Canada's foremost specialist care provider in diabetes and endocrinology. The screening program is being led by DIAGNOS' exclusive Canadian distribution partner, Labtician Ophthalmics, a Canadian-based provider and manufacturer of medical devices and pharmaceutical eye care products, with support from the Coordinated Accessible National (CAN) Health Network, a national federally-funded organization focused on helping scale Canada's most promising health care technologies. The partner's Endocrinologists, many of whom are nationally renowned for their areas of expertise, are supported by an interdisciplinary team of highly qualified Physician Assistants, Diabetes Educators (Registered Nurses, Registered Dietitians, Pharmacists), Optometrists, Chiropodists and Clinical Research Professionals.

The partner has 13 clinics, 20 clinical research sites, and provide care to over 77,000 patients across Canada annually. The CAN Health Network's primary goals are to create economic prosperity by scaling Canadian technology companies and stimulating the creation of domestic Canadian jobs. It does this by helping companies overcome the most common barriers they face in the adoption of new technologies in the Canadian healthcare system.

DIAGNOS' AI-driven retina analysis platform is designed to revolutionize the diagnosis and monitoring of retinal conditions, especially for individuals affected by diabetes and hypertension. By implementing AI algorithms, DIAGNOS' platform empowers healthcare professionals to detect retinal changes in their early stages, allowing for timely intervention and prevention of vision loss. This collaboration underscores the synergy between DIAGNOS' expertise in AI-driven healthcare solutions, labtician Ophthalmics dedication to providing accessible and comprehensive care for patients with diabetes and endocrine disorders, and the CAN Health Network's commitment to supporting Canada's leading technology companies.

By combining cutting-edge technology with medical expertise, the partnership aims to profoundly impact the lives of patients across Canada.